You are here: Industry Insights > BMS

News List

BMS receives offer from Taisho to purchase UPSA cphi-online
January 02, 2019
The potential transaction would position BMS to further refine its portfolio to focus on transformational medicines for patients facing serious diseases.
BMS confirms Taisho’s $1.6bn offer for UPSA pharmaphorum
December 21, 2018
After protracted speculation, Bristol-Myers Squibb has confirmed it plans to divest its French over-the-counter (OTC) medicines business UPSA to Japan’s Taisho Pharma in a $1.6 billion deal.
BMS looks to RNA splicing to boost immunotherapies pharmaphorum
December 19, 2018
Bristol-Myers Squibb’s quest to claim dominance in the immunotherapy space continues through a new collaboration with Eisai and its US-based precision medicine subsidiary H3 Biomedicine to.....
BMS and Infinity trial immunotherapy combo in bladder cancer pharmaphorum
December 14, 2018
Bristol-Myers Squibb has broadened a collaboration with Infinity Pharmaceuticals as it seeks to find combinations that boost the potency of its cancer immunotherapy, Opdivo.
BMS sponsors TV host Robin Roberts’ docuseries fiercepharma
December 05, 2018
Bristol-Myers Squibb has teamed up with ABC's "Good Morning America" co-anchor Robin Roberts to spotlight ordinary yet extraordinary people who’ve risen above and beyond major challenges.
Opdivo to be made available to UK melanoma patients via the Cancer Drugs Fund pharmafile
December 03, 2018
Bristol-Myers Squibb’s blockbuster immunotherapy Opdivo (nivolumab) is set to be made available to patients in the UK via the Cancer Drugs Fund as a treatment option for melanoma, NICE has revealed...
Bristol-Myers Squibb's Opdivo combination fails maintenance therapy trial in small-cell lung cancer firstwordpharma
November 27, 2018
Bristol-Myers Squibb announced Monday that the PD-1 inhibitor Opdivo (nivolumab) in combination with its CTLA-4 inhibitor Yervoy (ipilimumab) failed to significantly
NICE rejects Opdivo for preventing melanoma recurrence pharmatimes
November 27, 2018
NHS funding for use of Bristol-Myers Squibb’s Opdivo as an adjuvant treatment for resected stage III and IV melanoma is being blocked by the National Institute for Health and Care Excellence.
Moments matter in BMS and Pfizer's latest afib effort fiercepharma
November 22, 2018
Pfizer and Bristol-Myers Squibb are taking on atrial fibrillation again with a new awareness campaign. Called “Matter of Moments...
Bristol-Myers Squibb laying off 69 employees in Florida in push to 'focus resources' fiercepharma
November 19, 2018
After opening an office in Tampa, Florida, in 2014 and filling hundreds of positions, Bristol-Myers Squibb plans to lay off dozens of employees there early next year.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 15 16 Next page